Literature DB >> 22328838

Second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer.

Vera Hirsh1.   

Abstract

Entities:  

Keywords:  Non-small-cell lung cancer; egfr mutation; erlotinib; gefitinib

Year:  2012        PMID： 22328838      PMCID： PMC3267586          DOI： 10.3747/co.19.959

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  4 in total

1.  Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.

Authors:  Dae Ho Lee; Keunchil Park; Joo Hang Kim; Jong-Seok Lee; Sang Won Shin; Jin-Hyoung Kang; Myung-Ju Ahn; Jin Seok Ahn; Cheolwon Suh; Sang-We Kim
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

2.  Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.

Authors:  Riichiroh Maruyama; Yutaka Nishiwaki; Tomohide Tamura; Nobuyuki Yamamoto; Masahiro Tsuboi; Kazuhiko Nakagawa; Tetsu Shinkai; Shunichi Negoro; Fumio Imamura; Kenji Eguchi; Koji Takeda; Akira Inoue; Keisuke Tomii; Masao Harada; Noriyuki Masuda; Haiyi Jiang; Yohji Itoh; Yukito Ichinose; Nagahiro Saijo; Masahiro Fukuoka
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544

3.  Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

Authors:  Edward S Kim; Vera Hirsh; Tony Mok; Mark A Socinski; Radj Gervais; Yi-Long Wu; Long-Yun Li; Claire L Watkins; Mark V Sellers; Elizabeth S Lowe; Yan Sun; Mei-Lin Liao; Kell Osterlind; Martin Reck; Alison A Armour; Frances A Shepherd; Scott M Lippman; Jean-Yves Douillard
Journal:  Lancet       Date:  2008-11-22       Impact factor: 79.321

Review 4.  Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer.

Authors:  Takayuki Kosaka; Ei Yamaki; Akira Mogi; Hiroyuki Kuwano
Journal:  J Biomed Biotechnol       Date:  2011-06-02
  4 in total
  3 in total

1.  Tyrosine Kinase Inhibitors in the Treatment of Choroidal Metastases from Non-Small-Cell Lung Cancer: A Case Report and Review of Literature.

Authors:  Akshay Gopinathan Nair; Haresh T Asnani; Vinod C Mehta; Siddharth V Mehta; Rima S Pathak; Amit H Palkar; Indumati Gopinathan
Journal:  Ocul Oncol Pathol       Date:  2016-09-14

2.  [Joint serum tumor markers serve as survival predictive model of erlotinib in the treatment of recurrent non-small cell lung cancer].

Authors:  Lan Shao; Wei Hong; Lei Zheng; Chunxiao He; Beibei Zhang; Fajun Xie; Zhengbo Song; Guangyuan Lou; Yiping Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-05

3.  Treating Choroidal Metastases and Improving Vision with Osimertinib in EGFR T790M-Mutated Lung Adenocarcinoma: A Case Report and Review of the Literature.

Authors:  Karim Keshwani; Kelsey A Roelofs; Gordon Hay; Rachel Lewis; Nick Plowman
Journal:  Ocul Oncol Pathol       Date:  2020-10-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.